Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regent CAR-T 001: BTKi/PD-1 Bridging and Maintenance with CAR-T in r/r B-NHL
NCT05871684Phase 2Unknown
- Sponsor
- Ruijin Hospital
- Start
- Jun 2023
- Primary completion
- May 2024
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in diffuse large B-cell lymphoma (DLBCL), sponsored by Ruijin Hospital. Primary endpoint: 3-month complete response rate. Status: unknown.
02
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05871684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05871684.